Millennium Management LLC raised its stake in Adaptimmune Therapeutics (NASDAQ:ADAP) by 36.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 805,595 shares of the biotechnology company’s stock after acquiring an additional 215,439 shares during the period. Millennium Management LLC owned about 0.86% of Adaptimmune Therapeutics worth $5,381,000 as of its most recent SEC filing.
A number of other large investors also recently made changes to their positions in the business. OxFORD Asset Management LLP grew its position in Adaptimmune Therapeutics by 30.1% in the third quarter. OxFORD Asset Management LLP now owns 45,238 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 10,471 shares during the period. Alps Advisors Inc. grew its position in Adaptimmune Therapeutics by 12.7% in the fourth quarter. Alps Advisors Inc. now owns 103,816 shares of the biotechnology company’s stock valued at $693,000 after acquiring an additional 11,716 shares during the period. Essex Investment Management Co. LLC grew its position in Adaptimmune Therapeutics by 19.6% in the fourth quarter. Essex Investment Management Co. LLC now owns 87,307 shares of the biotechnology company’s stock valued at $583,000 after acquiring an additional 14,311 shares during the period. Raymond James & Associates bought a new stake in Adaptimmune Therapeutics in the fourth quarter valued at $114,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Adaptimmune Therapeutics in the third quarter valued at $182,000. Hedge funds and other institutional investors own 55.50% of the company’s stock.
Shares of NASDAQ:ADAP opened at $12.36 on Tuesday. Adaptimmune Therapeutics has a fifty-two week low of $4.28 and a fifty-two week high of $13.41. The firm has a market capitalization of $1,166.44, a price-to-earnings ratio of -15.45 and a beta of 1.16.
A number of analysts have weighed in on the company. BidaskClub upgraded Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. ValuEngine upgraded Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. Leerink Swann reiterated an “outperform” rating on shares of Adaptimmune Therapeutics in a research report on Thursday, March 15th. Finally, Zacks Investment Research cut Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $11.58.
In other Adaptimmune Therapeutics news, major shareholder Enterprise Associates 14 New acquired 1,268,508 shares of Adaptimmune Therapeutics stock in a transaction on Friday, March 23rd. The shares were bought at an average price of $1.91 per share, with a total value of $2,422,850.28. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Orbimed Advisors Llc sold 1,048,067 shares of the business’s stock in a transaction on Thursday, March 29th. The stock was sold at an average price of $11.50, for a total value of $12,052,770.50. The disclosure for this sale can be found here. In the last three months, insiders acquired 9,385,254 shares of company stock worth $17,966,655. Insiders own 24.45% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. and international copyright & trademark law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/17/millennium-management-llc-grows-stake-in-adaptimmune-therapeutics-adap.html.
Adaptimmune Therapeutics Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary SPEAR T-cell platform. Its platform enables to identify cancer targets; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.